Use of Non-Pharmacological Approaches for Migraine Treatment: Results from the Migraine in Aotearoa New Zealand Survey
Abstract
:1. Introduction
- Assess the use of supplements and complementary therapies (overall and for specific therapies) for migraine prevention, compared to prescribed medication.
- Compare the use of supplements and complementary therapies in those with a high frequency of monthly headache days (15 days or more a month) to those with headache on 14 days or fewer a month.
- Document reasons for discontinuing non-pharmacological treatments and assess potential unmet need (those who had not previously used these treatments but would like to).
2. Materials and Methods
2.1. Study Population and Recruitment
2.2. Survey Development and Content
2.3. Data Analysis
3. Results
3.1. Survey Respondents
3.2. Supplement Use
3.3. Complementary Therapy Use
3.4. Combined Use of Preventive Treatments
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
CGRP | Calcitonin gene-related peptide |
MFANZ | Migraine Foundation Aotearoa New Zealand |
NZ | Aotearoa New Zealand |
References
- Steiner, T.J.; Husøy, A.; Stovner, L.J. GBD2021: Headache Disorders and Global Lost Health—A Focus on Children, and a View Forward. J. Headache Pain. 2024, 25, 91. [Google Scholar] [CrossRef] [PubMed]
- Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021 (GBD 2021) Results. 2024. Available online: https://vizhub.healthdata.org/gbd-results/ (accessed on 12 June 2024).
- Garrett, S.M.; Imlach, F. The Impact of Living with Migraine Disease in Aotearoa New Zealand. N. Z. Med. J. 2024, 137, 54–76. [Google Scholar] [CrossRef] [PubMed]
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd Edition. Cephalalgia 2018, 38, 1–211. [Google Scholar] [CrossRef] [PubMed]
- Lipton, R.B.; Manack Adams, A.; Buse, D.C.; Fanning, K.M.; Reed, M.L. A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability. Headache 2016, 56, 1280–1289. [Google Scholar] [CrossRef] [PubMed]
- Ailani, J.; Burch, R.C.; Robbins, M.S. The American Headache Society Consensus Statement: Update on Integrating New Migraine Treatments into Clinical Practice. Headache J. Head Face Pain 2021, 61, 1021–1039. [Google Scholar] [CrossRef]
- Manack Adams, A.; Lanteri-Minet, M.; Leroux, E.; Katsarava, Z.; Lipton, R.B.; Sakai, F.; Matharu, M.; Fanning, K.; Sommer, K.; Seminerio, M.; et al. Characterizing Barriers to Care in Migraine: Multicountry Results from the Chronic Migraine Epidemiology and Outcomes-International (CaMEO-I) Study. J. Headache Pain 2024, 25, 134. [Google Scholar]
- Groth, M.; Katsarava, Z.; Ehrlich, M. Results of the GErman Migraine PatIent Survey on Medical Care and PrOPhylactic Treatment Experience (EPISCOPE). Sci. Rep. 2022, 12, 4589. [Google Scholar] [CrossRef]
- Hepp, Z.; Bloudek, L.M.; Varon, S.F. Systematic Review of Migraine Prophylaxis Adherence and Persistence. J. Manag. Care Pharm. 2014, 20, 22–33. [Google Scholar] [CrossRef]
- Hepp, Z.; Dodick, D.W.; Varon, S.F.; Chia, J.; Matthew, N.; Gillard, P.; Hansen, R.N.; Devine, E.B. Persistence and Switching Patterns of Oral Migraine Prophylactic Medications among Patients with Chronic Migraine: A Retrospective Claims Analysis. Cephalalgia 2017, 37, 470–485. [Google Scholar] [CrossRef]
- Imlach, F.; Garrett, S. Use of Medications for Migraine in Aotearoa New Zealand. N. Z. Med. J. 2024, 137, 65–87. [Google Scholar] [CrossRef]
- Wells, R.E.; Beuthin, J.; Granetzke, L. Complementary and Integrative Medicine for Episodic Migraine: An Update of Evidence from the Last 3 Years. Curr. Pain Headache Rep. 2019, 23, 10. [Google Scholar] [CrossRef] [PubMed]
- Patel, P.; Minen, M.T. Complementary and Integrative Health Treatments for Migraine. J. Neuroophthalmol. 2019, 39, 360–369. [Google Scholar] [CrossRef]
- Kuruvilla, D.; Erwin Wells, R. Evidence-Based Integrative Treatments for Headache. Headache J. Head Face Pain 2019, 59, 971–972. [Google Scholar] [CrossRef]
- Millstine, D.; Chen, C.Y.; Bauer, B. Complementary and Integrative Medicine in the Management of Headache. BMJ 2017, 357, j1805. [Google Scholar] [CrossRef]
- Karakurum Göksel, B. The Use of Complementary and Alternative Medicine in Patients with Migraine. Arch. Neuropsychiatry 2012, 50, S41–S46. [Google Scholar] [CrossRef] [PubMed]
- Posadzki, P.; Albedah, A.M.; Khalil, M.M.; Alqaed, M.S.; Lee, M.S.; Ernst, E.; Car, J. Complementary and Alternative Medicine for the Prevention and Treatment of Migraine Headache: An Overview of Systematic Reviews. Focus Altern. Complement. Ther. 2015, 20, 58–73. [Google Scholar] [CrossRef]
- Han, X.; Yu, S. Non-Pharmacological Treatment for Chronic Migraine. Curr. Pain. Headache Rep. 2023, 27, 663–672. [Google Scholar] [CrossRef]
- Moisset, X.; Pereira, B.; Ciampi De Andrade, D.; Fontaine, D.; Lantéri-Minet, M.; Mawet, J. Neuromodulation Techniques for Acute and Preventive Migraine Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Headache Pain 2020, 21, 142. [Google Scholar] [CrossRef]
- Gaul, C.; Eismann, R.; Schmidt, T.; May, A.; Leinisch, E.; Wieser, T.; Evers, S.; Henkel, K.; Franz, G.; Zierz, S. Use of Complementary and Alternative Medicine in Patients Suffering from Primary Headache Disorders. Cephalalgia 2009, 29, 1069–1078. [Google Scholar] [CrossRef]
- Rossi, P.; Di Lorenzo, G.; Malpezzi, M.G.; Faroni, J.; Cesarino, F.; Di Lorenzo, C.; Nappi, G. Prevalence, Pattern and Predictors of Use of Complementary and Alternative Medicine (CAM) in Migraine Patients Attending a Headache Clinic in Italy. Cephalalgia 2005, 25, 493–506. [Google Scholar] [CrossRef]
- Lambert, T.D.; Morrison, K.E.; Edwards, J.; Clarke, C.E. The Use of Complementary and Alternative Medicine by Patients Attending a UK Headache Clinic. Complement. Ther. Med. 2010, 18, 128–134. [Google Scholar] [CrossRef] [PubMed]
- Wells, R.E.; Bertisch, S.M.; Buettner, C.; Phillips, R.S.; Mccarthy, E.P.; Bertisch, S.M.; Buettner, C.; Phillips, R.S.; Mccarthy, E.P. Complementary and Alternative Medicine Use Among Adults With Migraines/Severe Headaches. Headache J. Head Face Pain 2011, 51, 1087–1097. [Google Scholar] [CrossRef]
- Marupuru, S.; Almatruk, Z.; Slack, M.K.; Axon, D.R. Use of Pharmacological and Non-Pharmacological Strategies by Community-Dwelling Adults to Manage Migraine: A Systematic Review. Clin. Pract. 2023, 13, 553–568. [Google Scholar] [CrossRef]
- Lipton, R.B.; Dodick, D.; Sadovsky, R.E.A.A.; Kolodner, K.; Endicott, J.; Hettiarachchi, J.; Harrison, W. A Self-Administered Screener for Migraine in Primary Care The ID MigraineTM Validation Study. Neurology 2003, 61, 375–382. [Google Scholar] [CrossRef] [PubMed]
- Cousins, G.; Hijazze, S.; Van De Laar, F.A.; Fahey, T. Diagnostic Accuracy of the ID Migraine: A Systematic Review and Meta-Analysis. Headache J. Head Face Pain 2011, 51, 1140–1148. [Google Scholar] [CrossRef] [PubMed]
- British Association for the Study of Headache (BASH). National Headache Management System for Adults 2019; British Association for the Study of Headache (BASH): Hull, UK, 2019. [Google Scholar]
- Diener, H.-C.; Holle-Lee, D.; Nägel, S.; Dresler, T.; Gaul, C.; Gö Bel, H.; Heinze-Kuhn, K.; Jü Rgens, T.; Kropp, P.; Meyer, B.; et al. Treatment of Migraine Attacks and Prevention of Migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin. Transl. Neurosci. 2019, 3, 1–40. [Google Scholar] [CrossRef]
- McInnernay, B.; Imlach, F.; Kennedy, J.; Garrett, S. Evaluating Barriers for Effective Migraine Management in Aotearoa New Zealand. J. Prim. Health Care 2024, 16, 347–356. [Google Scholar] [CrossRef]
- Probyn, K.; Bowers, H.; Mistry, D.; Caldwell, F.; Underwood, M.; Patel, S.; Sandhu, H.K.; Matharu, M.; Pincus, T. Non-Pharmacological Self-Management for People Living with Migraine or Tension-Type Headache: A Systematic Review Including Analysis of Intervention Components. BMJ Open 2017, 7, e016670. [Google Scholar] [CrossRef]
- Tepper, S.J.; Cirillo, J.; Kim, E.; L’Italien, G.; Tweedie, J.M.; Lodaya, K.; Riley, D.; Pathan, F.; Antaki, N.; Nathanson, B.H.; et al. The Temporal Trend of Placebo Response in Migraine Prevention from 1990 to 2021: A Systematic Literature Review and Meta-Analysis with Regression. J. Headache Pain 2023, 24, 54. [Google Scholar] [CrossRef]
- Sanderson, J.; Imlach, F.; Kennedy, J.; Garrett, S. Primary Care Clinicians’ Perspectives on Migraine Management in Aotearoa New Zealand: A Qualitative Study. J. Prim. Health Care 2024. under review. [Google Scholar]
- IPSOS Global Health Service Monitor. IPSOS Health Service Report 2024. New Zealand Edition; IPSOS: Auckland, New Zealand, 2024. [Google Scholar]
- Dumkrieger, G.M.; Ishii, R.; Goadsby, P.J. Flexible Modeling of Headache Frequency Fluctuations in Migraine with Hidden Markov Models. Headache J. Head Face Pain 2025, 65, 132–142. [Google Scholar] [CrossRef]
- Serrano, D.; Lipton, R.B.; Scher, A.I.; Reed, M.L.; Stewart, W.F.; Manack Adams, A.; Buse, D.C. Fluctuations in Episodic and Chronic Migraine Status over the Course of 1 Year: Implications for Diagnosis, Treatment and Clinical Trial Design. J. Headache Pain. 2017, 18, 101. [Google Scholar] [CrossRef] [PubMed]
- Dong, L.; Dong, W.; Jin, Y.; Jiang, Y.; Li, Z.; Yu, D. The Global Burden of Migraine: A 30-Year Trend Review and Future Projections by Age, Sex, Country, and Region. Pain Ther. 2024, 14, 297–315. [Google Scholar] [CrossRef] [PubMed]
- May, A.; Schulte, L.H. Chronic Migraine: Risk Factors, Mechanisms and Treatment. Nat. Rev. Neurol. 2016, 12, 455–464. [Google Scholar] [CrossRef]
- Adams, A.M.; Buse, D.C.; Leroux, E.; Lanteri-Minet, M.; Sakai, F.; Matharu, M.S.; Katsarava, Z.; Reed, M.L.; Fanning, K.; Sommer, K.; et al. Chronic Migraine Epidemiology and Outcomes—International (CaMEO-I) Study: Methods and Multi-Country Baseline Findings for Diagnosis Rates and Care. Cephalalgia 2023, 43. [Google Scholar] [CrossRef]
- Migraine Foundation Aotearoa New Zealand. New Migraine Questions in the Next New Zealand Health Survey; Migraine Foundation Aotearoa New Zealand: Auckland, New Zealand, 2023. [Google Scholar]
- Kubota, G.T. It Is Time Anti-CGRP Monoclonal Antibodies Be Considered First-Line Prophylaxis for Migraine. Arq. Neuropsiquiatr. 2022, 80, 218–226. [Google Scholar] [CrossRef] [PubMed]
- Sacco, S.; Amin, F.M.; Ashina, M.; Bendtsen, L.; Deligianni, C.I.; Gil-Gouveia, R.; Katsarava, Z.; MaassenVanDenBrink, A.; Martelletti, P.; Mitsikostas, D.-D.; et al. European Headache Federation Guideline on the Use of Monoclonal Antibodies Targeting the Calcitonin Gene Related Peptide Pathway for Migraine Prevention—2022 Update. J. Headache Pain 2022, 23, 67. [Google Scholar] [CrossRef]
- Charles, A.C.; Digre, K.B.; Goadsby, P.J.; Robbins, M.S.; Hershey, A. Calcitonin Gene-Related Peptide-Targeting Therapies Are a First-Line Option for the Prevention of Migraine: An American Headache Society Position Statement Update. Headache J. Head Face Pain 2024, 64, 333–341. [Google Scholar] [CrossRef]
Characteristic | Headache 15+ Days/Month (n/col%) | Headache <15 Days/Month (n/col%) | Total (n/col%) |
---|---|---|---|
Age group | |||
<18 years | 1 (1%) | 1 (<1%) | 2 (<1%) |
18−24 years | 5 (4%) | 15 (4%) | 20 (4%) |
25−34 years | 16 (14%) | 64 (16%) | 80 (15%) |
35−44 years | 30 (25%) | 93 (23%) | 123 (23%) |
45−54 years | 35 (30%) | 120 (29%) | 155 (29%) |
55−64 years | 15 (13%) | 55 (13%) | 70 (13%) |
65+ years | 7 (6%) | 24 (6%) | 31 (6%) |
Missing data | 9 (8%) | 40 (10%) | 49 (9%) |
Gender | |||
Female | 96 (81%) | 337 (82%) | 433 (82%) |
Male | 10 (9%) | 31 (8%) | 41 (8%) |
Another gender | 3 (3%) | 5 (1%) | 8 2%) |
Missing data | 9 (8%) | 39 (10%) | 48 (9%) |
Prioritized ethnicity * | |||
Māori | 7 (6%) | 32 (8%) | 39 (7%) |
Pacific | 0 (0%) | 6 (2%) | 6 (1%) |
Asian | 2 (2%) | 21 (5%) | 23 (4%) |
NZ European/Other | 99 (84%) | 310 (75%) | 409 (77%) |
Missing data | 10 (9%) | 43 (10%) | 53 (10%) |
Total | 118 | 412 | 530 |
Headache 15+ Days/Month (n/col%) | Headache <15 Days/Month (n/col%) | Total (n/col%) | Chi-Square | |
---|---|---|---|---|
Use of supplements 1 | ||||
Current use | 62 (56%) | 178 (47%) | 240 (49%) | |
Previous use | 47 (42%) | 150 (40%) | 197 (40%) | |
Never used | 2 (2%) | 49 (13%) | 51 (11%) | 11.725, p = 0.003 |
Use of complementary therapies 2 | ||||
Current use | 73 (66%) | 212 (56%) | 285 (58%) | |
Previous use | 32 (29%) | 101 (27%) | 133 (27%) | |
Never used | 6 (5%) | 67 (18%) | 73 (15%) | 10.27, p = 0.006 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Imlach, F.; Garrett, S. Use of Non-Pharmacological Approaches for Migraine Treatment: Results from the Migraine in Aotearoa New Zealand Survey. J. Clin. Med. 2025, 14, 4023. https://doi.org/10.3390/jcm14124023
Imlach F, Garrett S. Use of Non-Pharmacological Approaches for Migraine Treatment: Results from the Migraine in Aotearoa New Zealand Survey. Journal of Clinical Medicine. 2025; 14(12):4023. https://doi.org/10.3390/jcm14124023
Chicago/Turabian StyleImlach, Fiona, and Susan Garrett. 2025. "Use of Non-Pharmacological Approaches for Migraine Treatment: Results from the Migraine in Aotearoa New Zealand Survey" Journal of Clinical Medicine 14, no. 12: 4023. https://doi.org/10.3390/jcm14124023
APA StyleImlach, F., & Garrett, S. (2025). Use of Non-Pharmacological Approaches for Migraine Treatment: Results from the Migraine in Aotearoa New Zealand Survey. Journal of Clinical Medicine, 14(12), 4023. https://doi.org/10.3390/jcm14124023